UHN's $35M Ajmera Transplant Institute: What It Could Mean for Organ Utilization

On October 28, 2026, UHN Foundation in Toronto announced a $35 million gift from the Ajmera family to establish the Ajmera Transplant Institute at University Health Network (UHN). It's worth a few minutes of an OPC's attention, even from the U.S. side of the border.

Up front: this is funding, not a new approved treatment. No new therapy or protocol was approved with this announcement. What it does is put serious resources behind research that could eventually change how many organs we're able to use.

The Facts

From the UHN Foundation news release and CityNews Toronto coverage:

• The $35 million gift brings the Ajmera family's cumulative giving to UHN to $62 million. UHN Foundation describes them as the largest known single-family philanthropic donors to transplant medicine globally.
• UHN performed a record 820 transplants in 2025–26, including the most lung transplants of anywhere in the world.
• UHN Foundation is launching a wider $100 million campaign for transplant medicine.
• The institute is meant to unite clinical care, engineering, immunology, regenerative medicine, cell therapy, and data science under one roof.
• Per CityNews, Premier Doug Ford cited UHN's goal of reaching 1,000 transplants per year.

The Research Themes

Based on the release and UHN Foundation's comments to CityNews, the work centers on:

• Organ preservation and ex-vivo perfusion. UHN is a global leader in this field, and the release notes ex-vivo perfusion was developed there.
• Less immunosuppression. UHN Foundation's CEO told CityNews they're working on "eliminating immunosuppressants" so patients can live post-transplant without the side effects.
• More compatible organs. The CEO also described work toward "making every organ a universal donor so that we can use more organs."
• Cellular therapies. The release highlights UHN's lab-grown insulin-producing cell trial in Type 1 diabetes.

These are research goals, not current clinical standards.

Why This Matters to OPCs

For those of us in procurement, the most relevant thread is organ utilization. Every coordinator has had a case where an organ was offered, discussed, and ultimately not used. Perfusion and reconditioning research is about changing that math: assessing, maintaining, and potentially repairing organs outside the body so more of them can be safely transplanted.

If that work keeps maturing, it could gradually affect:

• How marginal organs are evaluated and offered.
• Recovery logistics and timing, including DCD cases.
• How much donor management data receiving centers want, and when.

None of that changes your protocols today. But it's a good reminder of why careful donor management and complete, accurate documentation matter: they're the foundation every downstream innovation builds on.

A Note on the Basics

New technology tends to raise the bar for fundamentals, not lower it. Donor management and allocation/recovery make up about two-thirds of the current CPTC outline. If you're building those foundations, the study resources page is a good place to start.

Brooke Wallace, BSN, RN, CCRN
Founder, CPTCexam.com
BrookeWallaceRN@gmail.com

Sources

• UHN Foundation via Cision/Newswire: $35 million gift from Ajmera family establishes UHN's Ajmera Transplant Institute (October 28, 2026)
• CityNews Toronto: Record-breaking $35M donation to UHN for new transplant institute (October 28, 2026)

Disclaimer: CPTCexam.com is an independent educational resource. This post summarizes publicly reported news for educational purposes and is not medical advice. It is not affiliated with or endorsed by University Health Network (UHN), UHN Foundation, or the American Board for Transplant Certification.